Hypothermia in a patient with Alzheimer’s disease receiving a combination therapy with risperidone and pipamperone

Kamp, Daniel; Paschali, Myrella; Supprian, Tillmann; Lange-Asschenfeldt, Christian

doi:10.1177/2045125315591916

Cited by 9 publications

(7 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For example, long-term hypothermia-mediated neuroprotection is a risk in the treatment of psychiatric patients with organic brain damage and may increase hypothermia susceptibility to antipsychotics [ 92 ]. These limitations are also applicable to patients with Alzheimer's disease [ 93 ]. Fortunately, the emerging role of RBM3 in hypothermia-induced neuroprotection offers the potential to identify new drugs without cooling to achieve the same goal.…”

Section: Rbm3 In Neuroprotectionmentioning

confidence: 99%

RNA binding motif protein 3: a potential biomarker in cancer and therapeutic target in neuroprotection

Zhou

Zhang

et al. 2017

Oncotarget

View full text Add to dashboard Cite

RNA binding motif 3 (RBM3) is a highly conserved cold-induced RNA binding protein that is transcriptionally up-regulated in response to harsh stresses. Featured as RNA binding protein, RBM3 is involved in mRNA biogenesis as well as stimulating protein synthesis, promoting proliferation and exerting anti-apoptotic functions. Nowadays, accumulating immunohistochemically studies have suggested RBM3 function as a proto-oncogene that is associated with tumor progression and metastasis in various cancers. Moreover, emerging evidences have also indicated that RBM3 is equally effective in neuroprotection. In the present review, we provide an overview of current knowledge concerning the role of RBM3 in various cancers and neuroprotection. Additionally, its potential roles as a promising diagnostic marker for cancer and a possible therapeutic target for neuro-related diseases are discussed.

show abstract

Section: Rbm3 In Neuroprotectionmentioning

confidence: 99%

RNA binding motif protein 3: a potential biomarker in cancer and therapeutic target in neuroprotection

Zhou

Zhang

et al. 2017

Oncotarget

View full text Add to dashboard Cite

show abstract

“…Three patients experienced a second hypothermic episode after they had switched to a different APD. Nevertheless, Chen et al ( 11 ), Kamp et al ( 34 , 35 ), and Goodbar et al ( 27 ) describe four cases in which hypothermia did not recur after lowering of the dose, while Özyurt et al ( 43 ) describe a case in which hypothermia did not recur after increasing the dose after an interval of 2 days.…”

Section: Resultsmentioning

confidence: 99%

Hypothermia due to Antipsychotic Medication: A Systematic Review

et al. 2017

View full text Add to dashboard Cite

BackgroundHypothermia is a rare, but potentially fatal adverse effect of antipsychotic drug (APD) use. Although the opposite condition, hyperthermia, has been researched extensively in the context of the malignant antipsychotic syndrome, little is known about hypothermia due to APDs.ObjectiveThis study aimed to review the literature on hypothermia in the context of APD use, and formulate implications for research and clinical care.MethodsA systematic search was made in PubMed and Ovid Medline.ResultsThe literature search yielded 433 articles, including 57 original case descriptions of hypothermia developed during APD use with non-toxic plasma levels. All cases together indicate that the risk of developing hypothermia is highest during the 7 days following initiation, or increase in dosage, of APDs, especially in the presence of additional predisposing factors, such as advanced age, exposure to cold, adjuvant use of benzodiazepines, and (subclinical) hypothyroidism. In addition, data derived from drug-monitoring agencies suggest that the prevalence of APD-related hypothermia is at least 10 times higher than suggested by the literature.ConclusionWe conclude that health-care professionals need to monitor the body temperature of patients starting with (an increased dose of) APDs for a duration of 7–10 days to prevent hypothermia, especially in the presence of multiple risk factors. Moreover, systematic studies are needed to establish the actual prevalence of APD-related hypothermia as well as the relative risk for individual APDs.

show abstract

“…Chlorpromazine was well‐known to reduce BCT since it was introduced in 1952 (Ban, 2007), when it was used in anesthesia to support body cooling during surgery (so‐called artificial hibernating) (López‐Muñoz et al., 2005). Nowadays, hypothermia has been reported in the context of the use of different, typical as well as atypical, APD (Szota & Araszkiewicz, 2019; van Marum et al., 2007; Zonnenberg et al., 2017) including haloperidol (Signorelli et al., 2013), clozapine (Papazisis et al., 2009), aripiprazole (Kozian et al., 2019), olanzapine (Kreuzer et al., 2012), pipamperone (Kamp, Paschali, & Lange‐Asschenfeldt, 2016), risperidone (Brandon Bookstaver & Miller, 2011) and combinations (Kamp, Paschali, Supprian, et al., 2016).…”

Section: Introductionmentioning

confidence: 99%

Characteristics of antipsychotic drug‐induced hypothermia in psychogeriatric inpatients

Kamp

Paschali

Bouanane

et al. 2021

Human Psychopharmacology

Self Cite

View full text Add to dashboard Cite

Objective Hypothermia is a potentially lethal adverse reaction to typical and atypical antipsychotic drugs (APD). Among predisposing factors are advanced age and comorbid somatic diseases. The aim of this study was to assess the incidence of hypothermia and quantify risk factors. Method Charts of N = 3002 psychogeriatric inpatients were screened for incidence of hypothermia (body core temperature <35.0°C). The frequency of hypothermia was compared between patients treated with versus without APD and, within the sample of APD‐treated patients, for (1) specific APD, (2) sex, (3) main diagnosis, and (4) age. Results N = 54 cases (2.6%) of hypothermia occurred in APD‐treated patients and 12 cases (1.3%) in non‐APD‐treated patients (p = 0.024). In APD‐treated patients, only male sex (p = 0.038) and pipamperone were associated with a higher incidence of hypothermia (p = 0.0017). Whereas the main diagnosis delirium showed a trend to significance, age did not correlate with hypothermia. Conclusion Medication with pipamperone was associated with an increased risk of hypothermia. The advanced age of our sample might as well explain the high incidence of hypothermia within our sample and the failure to detect high age as a risk factor due to a ceiling effect.

show abstract

Hypothermia in a patient with Alzheimer’s disease receiving a combination therapy with risperidone and pipamperone

Cited by 9 publications

References 5 publications

RNA binding motif protein 3: a potential biomarker in cancer and therapeutic target in neuroprotection

RNA binding motif protein 3: a potential biomarker in cancer and therapeutic target in neuroprotection

Hypothermia due to Antipsychotic Medication: A Systematic Review

Characteristics of antipsychotic drug‐induced hypothermia in psychogeriatric inpatients

Contact Info

Product

Resources

About